Making Sense

Alex Gorsky discusses reshoring pharmaceutical supply chains and AI's role in drug discovery

15 min Listen to the original Episode page
PharmaceuticalsSupply ChainArtificial IntelligenceHealthcare PolicyGlobal Trade

Summary

Former J&J CEO Alex Gorsky argues that the COVID-19 pandemic shifted board priorities from supply chain efficiency to resilience. He highlights a critical dependency on foreign sources for generic drugs, noting that approximately 85% of US drug volume consists of generics sourced internationally. Gorsky advocates for a multifaceted approach to reshoring, including strategic stockpiles and coordination with allied nations. He also predicts that AI will drastically reduce drug discovery timelines by synthesizing complex biological datasets. The discussion concludes with advice for healthcare leaders to prioritize patience and innovation.

Key takeaways

  1. 1
    Approximately 85% of drug volume in the US (including antihypertensives, statins, anticoagulants, and pain medications) consists of generics sourced from outside the US, while only 15% is branded volume produced by major strategics.

    Unidentified speaker (speaker_1) · 2:47

  2. 2
    The government has taken steps on strategic stockpiles, but Gorsky suggests extending these to address near-term challenges and potential interruptions.

    Unidentified speaker (speaker_1) · 5:09

Episode sections

  1. 0:00 – 0:45

    Introduction and Guest Background

    Jerry Lee introduces Alex Gorsky, former chairman and CEO of Johnson & Johnson, highlighting his tenure and current role on J.P. Morgan’s SRI Advisory Council. The introduction sets the stage for discussing healthcare resilience and supply chain risks.

  2. 0:45 – 2:06

    Post-Pandemic Supply Chain Risk Calculus

    Gorsky identifies COVID-19 as a seminal event that exposed risks in globalization and transportation lines. He states that boards are now prioritizing resiliency and redundancy over pure efficiency and effectiveness in healthcare supply chains.

  3. 2:06 – 4:14

    Generic Drug Dependency and Choke Points

    Gorsky notes that while branded drugs have shifted some production to the US, the majority of generic drugs (antihypertensives, statins, anticoagulants, pain meds) are still sourced from outside the US. He identifies this imbalance as a key bottleneck.

  4. 4:14 – 6:51

    Solving the Economics of Reshoring

    Addressing the high cost of domestic manufacturing, Gorsky argues for a multifaceted approach involving strategic stockpiles, international capacity coordination, and bringing manufacturing back to the US to support innovation and patient protection.

  5. 6:51 – 8:00

    Next-Generation Manufacturing Challenges

    Gorsky highlights the challenge of creating next-generation manufacturing facilities in the US. He notes that while new approaches are cleaner and more flexible, they face traditional financial hurdles like DCF/NPV models that may not capture strategic value.

  6. 8:00 – 9:44

    Reshoring vs. Friendshoring Strategy

    Gorsky suggests reserving some supply chain capacity for US production during emergencies while utilizing trusted partners abroad for the long term. He emphasizes coordinating with existing CMOs/CDMOs in the US and working with allies like Europe and Mexico.

  7. 9:44 – 13:26

    AI in Drug Discovery and Development

    Gorsky describes AI as revolutionary for drug discovery, particularly in synthesizing large datasets (genotypic, phenotypic, imaging) to uncover insights. He predicts AI will significantly reduce the time to identify and filter compounds from years to months.

  8. 13:26 – 14:59

    Advice for Healthcare Leaders

    Gorsky advises healthcare CEOs and CFOs to keep patience at the center of their operations and maintain a relentless focus on innovation across technology, access, and company function to improve patient outcomes.

Assets discussed

AssetKindStanceContext
JOHNSON & JOHNSONJNJequityneutralThanks so much again for doing this. I think just to wrap things up, I'd love to ask for advice on behalf of our CEOs and CFOs in healthcare, biopharma and otherwise. I mean from J and J and otherwise, you've navigated the industry through financial crises, patent cliffs, a pandemic you referred to earlier, and obviously a fundamental rethink of globalization.

“Stance” is how the speakers talked about the asset, not a recommendation.

Claims worth verifying

COVID-19 was a seminal point in time that exposed risks in globalization, transportation lines, and global policies, causing boards to rethink efficiency versus resiliency.

Unidentified speaker (speaker_1) ·1:06

How to verify: Review post-pandemic supply chain reports from healthcare industry associations (e.g., PhRMA, BIO) or SEC 10-K filings of major pharma companies discussing supply chain risk factors. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

Primary source

On any given day, almost 85% of drug volume in the US (antihypertensives, statins, anticoagulants, pain meds) is generic and sourced from outside the US, while 15% is branded volume.

Unidentified speaker (speaker_1) ·2:47

How to verify: Verify against FDA Drug Shortages reports, IMS Health market data, or CDC/NDC data on prescription volumes and manufacturing origins. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

Major strategics have shifted some production of final products and APIs to the US, but the majority of generic drugs remain sourced internationally.

Unidentified speaker (speaker_1) ·3:32

How to verify: Check SEC filings (10-K, 10-Q) of major branded pharma companies (e.g., J&J, Pfizer, Merck) for disclosures on manufacturing locations and supply chain diversification. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

Primary source

Reshoring requires strategic stockpiles, international capacity coordination, and long-term domestic manufacturing investment.

Unidentified speaker (UNKNOWN) ·4:39

How to verify: Review government policy documents (e.g., FDA Modernization Act 2.0, National Biodefense Strategy) and industry white papers on supply chain resilience. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

Next-generation manufacturing facilities are more efficient, cleaner, and greener than previous methods.

Unidentified speaker (speaker_1) ·7:10

How to verify: Compare environmental impact reports and manufacturing efficiency metrics from companies adopting continuous manufacturing or modular facilities versus traditional batch processing. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

AI can reduce the time to identify and filter compounds from three years to a couple of months.

Unidentified speaker (speaker_1) ·12:09

How to verify: Review case studies or publications from AI-driven drug discovery companies (e.g., Insilico Medicine, Recursion) comparing traditional vs. AI-accelerated hit-to-lead timelines. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

AI synthesizes genotypic, phenotypic, and imaging data to uncover insights into disease biology.

Unidentified speaker (speaker_1) ·11:10

How to verify: Examine research papers or product documentation from AI healthcare platforms (e.g., DeepMind, Tempus) detailing their data integration capabilities. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

Alex Gorsky served as chairman and CEO of Johnson & Johnson.

Unidentified speaker (UNKNOWN) ·0:07

How to verify: Check Johnson & Johnson investor relations history or SEC proxy statements for leadership tenure dates. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

Primary source

Alex Gorsky is a member of J.P. Morgan’s SRI Advisory Council.

Unidentified speaker (UNKNOWN) ·0:00

How to verify: Verify via J.P. Morgan press releases or website announcements regarding the SRI Advisory Council membership. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

The podcast was recorded on October 12, 2026.

Unidentified speaker (UNKNOWN) ·0:00

How to verify: Check the podcast episode metadata or J.P. Morgan press release for the recording date. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

Do your own research

  • Verify the 85% generic import dependency statistic using FDA drug shortage reports or industry analyses from IQVIA or EvaluatePharma.
  • Review Johnson & Johnson's latest 10-K filing for details on their manufacturing footprint and supply chain risk disclosures.
  • Check recent FDA initiatives on strategic stockpiles and domestic API manufacturing incentives.
  • Analyze public company filings (10-K/10-Q) of major generic drug manufacturers for geographic revenue and production concentration.
  • Research AI drug discovery startups' clinical trial success rates compared to traditional pharma pipelines.
  • Assess geopolitical risks in key API-producing countries like China and India using trade data from the US Census Bureau.
  • Look for counter-arguments on the economic viability of reshoring vs. friendshoring in healthcare supply chains.
  • Review J.P. Morgan's SRI Advisory Council publications for any conflicts of interest or biases in Gorsky's current advisory role.
Full transcriptexpand
0:00
Unidentified speaker (UNKNOWN): Today,
0:00
Unidentified speaker (speaker_0): I'm pleased to be joined by Alex Gorsky, a globally recognized business leader who previously served as chairman and CEO of Johnson
0:07
Unidentified speaker (UNKNOWN): ⁇
0:07
Unidentified speaker (speaker_0): Johnson, one of the world's largest and most recognized healthcare companies. Over the course of his tenure, Alex helped guide the organization through periods of significant complexity and change, strengthening strategic focus, advancing innovation, and leading with a strong emphasis on trust, governance, and long-term long term value creation. Today, Alex brings a unique vantage point.
0:27
Unidentified speaker (speaker_0): at the intersection of healthcare, technology, and global risk. And I'm thrilled to welcome him, looking forward to his perspectives on how leaders can navigate disruption while building resilient, mission driven organizations. Alex, thank you again for being here today.
0:41
Unidentified speaker (UNKNOWN): Well,
0:41
Unidentified speaker (speaker_1): thank you for the generous introduction, Jerry. I really look forward to our discussion.
0:45
Unidentified speaker (speaker_0): The seed question we've been carrying into the this series is how the industry's dependence on overseas API manufacturing. has fundamentally changed the way that pharma boards think about risk. Take us into the room where it happens, meaning how has the calculus round cost, single sourcing, geographic concentration, evolved in the boredom of the last five years? And actually importantly,
1:04
Unidentified speaker (speaker_0): what's changed most since COVID?
1:06
Unidentified speaker (speaker_1): I think that COVID-19 was really a seminal point in time for the world, let alone the healthcare system. Suddenly we realized that the dependency, the consistency of globalization was put somewhat at risk by the way we were dealing with transportation lines, uh, let alone
1:26
Unidentified speaker (speaker_1): other policies on a global basis in the middle of the pandemic, that I think has really resulted in CEOs, boards, and other industry leaders rethinking to say we need to not only focus on a efficiency and effectiveness, but we also need to think about resiliency and redundancy, particularly when we're talking about the healthcare of our nation.
1:46
Unidentified speaker (speaker_0): I couldn't agree more. I think that we've been in a place where effectively market forces have almost encouraged the offshoring, a lot of these core competencies that really were inside our borders generations ago. So, Alex, when people hear pharma supply chain. they're usually thinking APIs, China-India
2:06
Unidentified speaker (speaker_0): concentration and the like. But I think the vulnerabilities are far, far, far deeper. You got precursor chemicals, you got fill and finish, you got glass and vials, cold chain logistics, sterile injectables, and the like. So from your years at the helm of JJ and now on our SRI Advisory Council, what do you think are the choke points that keep you up at night? And what's most unappreciated by the market
2:26
Unidentified speaker (speaker_0): and policymakers?
2:27
Unidentified speaker (speaker_1): I think the fact of the matter is, over the last several decades, the supply component for many of these drugs was really driven by low cost and frankly concerns about certain environmental issues and the challenges of producing some of these chemicals here in the United States. And I
2:47
Unidentified speaker (speaker_1): think now what we've seen is a shift in that discussion. And it's important to understand the issue at hand and that if you we look at the entire drug supply in the United States, on any given day, almost 85% of the drugs. So think the antihypertensive, the statins, the anticoagulants, you
3:07
Unidentified speaker (speaker_1): know, pain medications are generic. And about 15%,
3:12
Unidentified speaker (speaker_1): okay, and this is of the volume. of what I'm talking about, not the dollars, but the volume, are in what I'd call branded drugs that are produced by the major strategics. And what you see is this imbalance where while many of the strategics have shifted some of the production, not only of their final product, but even of their
3:32
Unidentified speaker (speaker_1): API, their active pharmaceutical ingredients and key starting materials here in the United States, on the over overwhelming majority of those generic drugs that are being used, those drugs continue to be sourced from places outside the United States. And that, in fact, is one of the key bottlenecks that we've identified
3:52
Unidentified speaker (speaker_1): and really are attempting to put together a strategic approach to say, how can we take a very reasonable, practical, pragmatic strategy to bring some of those back to the United States, to look for other sources around the world, to make sure that we're never dependent on just one site, one location,
4:12
Unidentified speaker (speaker_1): particularly when you're thinking about the health of our country?
4:14
Unidentified speaker (speaker_0): Alex, reshoring critical medicines and building redundant supply networks is a core SRA thesis, as you know. But the economics are hard, domestic manufacturing is more expensive, payers push back on price and shareholders obviously reward capital. efficiency. So obviously, given all of your experiences, how do you see the industry solving that equation? Is it is it public-private partnerships? Is it advanced purchase agreements,
4:34
Unidentified speaker (speaker_0): tax incentives, tariff protections, private capital? And what's the right role for each?
4:39
Unidentified speaker (UNKNOWN): Well,
4:39
Unidentified speaker (speaker_1): Joey, I think it's all the above is the short answer. Sure. Uh there's not just, you know, one switch we're going to be able to flip and change the situation overnight. It's taken us decades to get to where we are. And given the complexity of some of the underlying science, the capabilities, the skill sets, let alone the public policy, pricing issues,
4:59
Unidentified speaker (speaker_1): financial, we're going to, I think, have to take a multifaceted approach to bring about the kind of change that we'd like to see over the next five or 10 years. So let me give you some concrete examples.
5:09
Unidentified speaker (UNKNOWN): I
5:09
Unidentified speaker (speaker_1): think look, number one starts with how can we make sure we've got the right strategic stockpiles? Here, the government has really taken some important steps, but there are others that we can take to definitely help extend, you know, some of the near-term, you might say, challenge that would face if there was some kind of an interruption. Next,
5:29
Unidentified speaker (speaker_1): I think it also is going to require us to work with other countries. Where is their additional capacity that currently exists in other countries? And by the way, some of that may exist in the United States, but it may be in companies who have not fully maximized a particular capacity. And how can we, through again, very thoughtful allocation and
5:48
Unidentified speaker (speaker_1): prioritization of some of these ingredients, make sure that we know where to go to immediately begin production or and set all the foundational requirements in place, whether it's a technology or regulatory? to make that feasible. And then, of course, we should also be look thinking long-term
6:08
Unidentified speaker (speaker_1): around what we can do to bring some of those manufacturing opportunities here to the United States. And I think that that is positive for a couple of reasons. One, it enables us to really do better in terms of innovation here in the US. I mean, having better innovation in the United States, particularly. around something like
6:27
Unidentified speaker (speaker_1): biopharmaceuticals and certain medical technology, what could be better when you think about it? Those are the kind of jobs, the kind of wherewithal that we want to have here. But that's going to take some time. And number two, to ensure that we're pr doing our job on protecting patients here in the United States from future interruptions in the supply.
6:45
Unidentified speaker (speaker_0): What do you think is going to be the most complicated, most challenging, get the most pushback of the levers you just mentioned?
6:51
Unidentified speaker (speaker_1): Well, each one of them has got a certain level of complexity. Sure. But, you know, clearly, I think probably the most ambitious is how do you take next generation manufacturing facilities and create them here in the United States? The good news is, is that there are new approaches in manufacturing that are much more
7:10
Unidentified speaker (speaker_1): efficient, that are arguably cleaner and greener than what we've seen in. previous. That allow more flexibility in terms of the amount of, for example, ingredients that need to be produced so that you could you could support a new startup biopharmaceutical company at a much lower cost rate so that perhaps they could
7:30
Unidentified speaker (speaker_1): get into the clinical trials even faster, but also do so at the scale for other products. I think therein lies the challenge and the opportunity is how do we bring these on board that if we just did your, you know, classic DCF NPV is going to be a bit more challenging. But when we think more strategically about its
7:50
Unidentified speaker (speaker_1): impact not only on our country, but on patients, but longer term on the industry, I think that, you know, again, there lies a great opportunity for us to be thinking about the future. Why
8:00
Unidentified speaker (speaker_0): don't we talk a little bit about reshoring versus friendshoring? And so some of the capacity we need may already exist with trusted partners abroad. Where do you draw the line between what must be made within the US and where building capacity with allies is actually the right answer?
8:15
Unidentified speaker (UNKNOWN): Well,
8:16
Unidentified speaker (speaker_1): look, ultimately I think we will need to reserve a certain amount of our supply chain for us to have US produce products across a broad range in the case of certain emergencies. And so that's going to be, it's going to be incumbent upon us to have the kind of flexibility and the skill sets to put that together if it's for a short period
8:36
Unidentified speaker (speaker_1): of time. To address the larger issue, though, over the next five, seven, 10 years, we're going to have to pull on all these levers. And um and again, I think it starts right here at home. We know, for example, that there are CMOs, C DMOs that have got excess capacity that's under or not being utilized. We know that there's manufacturing
8:55
Unidentified speaker (speaker_1): capacity in large strategics right now. You know, we could do a better job of utilizing. The key is how do we coordinate that? How do we get people to talk across company, across industry, frankly, across our healthcare system so that we can make some of those shifts and moves that would ultimately be required, you know, practical. and that we could
9:15
Unidentified speaker (speaker_1): actually put into place. Next, of course, it's about, you know, working with other countries. And here too, I've got to think that that's a great opportunity for the US and Europe to work together, for us to work with Mexico, for example, places in the Caribbean. Again, I think working on a number of different options in parallel, Parallels simultaneously, is likely going to
9:35
Unidentified speaker (speaker_1): give us the best chance of really taking on this big problem. As you say, how do you eat an elephant one bite at a time? I think that's the way we're going to need to go about this as well.
9:44
Unidentified speaker (speaker_0): AI is top of mind for everyone in healthcare and outside of healthcare. You know, our own pillar as we think about it, we're focused on preparedness for future health threats, not just today's shortages. So, how do you see advances in AI driven discovery, distributed manufacturing, uh, platforms, biosecurity, changing what a resilient healthcare system looks like.
10:03
Unidentified speaker (speaker_0): And how should investors be positioning for AI in general?
10:08
Unidentified speaker (UNKNOWN): Well,
10:08
Unidentified speaker (speaker_1): look, I think fundamentally AI is going to have a revolutionary impact on all those areas. Now, I would balance that by also saying, as is the case for most very significant technology inflection points, is they tend to take a little bit longer initially, just because of friction points that could be the technology itself. but it can be the
10:27
Unidentified speaker (speaker_1): economics, it can be laws, policy.
10:31
Unidentified speaker (UNKNOWN): But
10:32
Unidentified speaker (speaker_1): then once they grab hold, they will actually accelerate much faster. Agreed. And I see that happening here too. And look, let's just start with the area of drug discovery. I've been privileged and honored to be part of this industry for more than three decades. But for more than two and a half decades, it's basically been finding a needle in a haystack. Understanding underlying biology,
10:52
Unidentified speaker (speaker_1): i.e., what's causing a disease and what is that particular receptor site that's not working or needs to be adjusted. How do we find a right modality? So it could be a protein, a peptide, an antibody that actually goes in and resolves that particular issue. Now,
11:09
Unidentified speaker (UNKNOWN): when
11:10
Unidentified speaker (speaker_1): we had data such as genotypic information, phenotypic information about what a patient's history looks like, imaging information, we can combine that all real time. And this is what AI is particularly well suited for, is to take large amounts of data, synthesize it to uncover new insights. I'm particularly excited whether
11:30
Unidentified speaker (speaker_1): again it's on the biology of understanding disease. You know, if you really dig into what we traditionally done, our understanding. of the underlying pathophysiology and biology of a disease is actually, you know, quite minimal. And I think we're going to see a massive transformation there.
11:48
Unidentified speaker (UNKNOWN): I
11:49
Unidentified speaker (speaker_1): think in this ability to either take organ organic existing compounds, or let's call it more AI design, bespoke compounds that will be more specifically engineered in the future to hopefully have a better safety efficacy profile, let alone manufacturability. Those are real opportunities
12:09
Unidentified speaker (speaker_1): for us to make a significant difference in how we really fundamentally think about disease and treatment options for those patients. We could take, for example, a timeline where normally once we've identified a site, Decide it could take us three years of prioritization and filtering. to find a compound that
12:28
Unidentified speaker (speaker_1): might be able to be done, let's call it a couple of months. That step alone will take a massive amount of time out of the system. And last but not least, while thinking about the science, we also need to think about the business models. And there's going to be a wide array of business models that could be partnerships, business partnerships that could be JVs, that could
12:48
Unidentified speaker (speaker_1): somewhere be, you know, new forms. of software, AI products, working our way through that on exactly how these are going to work. Again, are going to create opportunities, could even create opportunities to reduce the costs and the levels of investment that hopefully could even have an impact on the cost of the therapeutics themselves.
13:06
Unidentified speaker (speaker_0): Thanks so much again for doing this. I think just to wrap things up, I'd love to ask for advice on behalf of our CEOs and CFOs in healthcare, biopharma and otherwise. I mean from J and J and otherwise, you've navigated the industry through financial crises, patent cliffs, a pandemic you referred to earlier, and obviously a fundamental rethink of globalization. If you were sitting across from a healthcare
13:26
Unidentified speaker (speaker_0): CEO or CFO today, what are two or three structural shifts you'd want them to focus on? What are just general pieces of advice that you'd have for them for the next couple of years?
13:35
Unidentified speaker (UNKNOWN): Well,
13:36
Unidentified speaker (speaker_1): look, I again I feel incredibly hard. humbled to have had the opportunity to work in this industry for the last three and a half decades and to see the changes that have come about, the new technologies, the new treatments has been nothing less than remarkable. So for that next generation of leaders, by the way, that I'm counting on, not only for myself, but for my
13:56
Unidentified speaker (speaker_1): family, is a couple things. One, always, always, always keep the patience at the center of what we're doing.
14:03
Unidentified speaker (UNKNOWN): I
14:04
Unidentified speaker (speaker_1): think it's an incredible source of inspiration in this industry to know that ultimately we're helping people live longer, healthier, and happier lives. What more important calling can you have? And this is not for just a customer. This is for somebody you know. I think the other piece of it is
14:24
Unidentified speaker (speaker_1): that just does not happen on its own. It takes a release. relentless focus on innovation, innovation in technology, innovation in how you get access and education for your products, innovation, the way you function as a company, always, you know, asking the question, what else can we be doing better? Having that sense of
14:43
Unidentified speaker (speaker_1): urgency, more important than ever.
14:45
Unidentified speaker (speaker_0): Alex, on behalf of Jake Morgan, Jake Morgan, SRI, and our broader team, want wanna to thank you for your time today. Always insightful, always amazing to have you. Thank you.
14:53
Unidentified speaker (speaker_1): Thank you, Jerry.
This page was produced automatically: the audio was transcribed with nvidia/parakeet-tdt-0.6b-v3+sortformer-v2.1 and interpreted by Qwen3.6-35B-A3B-UD-IQ3_S.gguf. Transcription and interpretation can contain errors; always confirm against the original episode. Nothing here is investment advice.

More from Making Sense

Making Sense

Financing the Future of Defense: Admiral Pierre Vandier on Innovation and Investment

Episode discussion: Admiral Vandier on NATO's shift to protracted warfare and the need for private capital in defense adoption

Speakers’ claims: Admiral Pierre Vandier, NATO's Supreme Allied Commander Transformation, argues that the war in Ukraine has shifted conflict from crisis management to protracted warfare, making industrial production capacity decisive. He notes that military R&D has lagged behind civilian innovation for 30 years, creating a cultural barrier to adopting new technologies like commercial drones. Vandier suggests that NATO's primary challenge is now adoption at scale, requiring a shift from innovation boards to adoption boards. He calls for private capital and banks to inject speed and new KPIs into the defense sector, moving investment from legacy systems to future technologies.

Defense IndustryNATOPrivate Capital
12 min0 assets7 claims to verify
Making Sense

Revving the ETF vehicle: Roundhill’s CEO on DRAM, next-gen innovation and more

Episode discussion: Roundhill CEO Dave Mazza discusses ETF innovation, DRAM exposure, and retail investor influence

Speakers’ claims: Dave Mazza, CEO of Roundhill, explains the firm's mission to serve millennial and Gen Z investors through de-aged financial advice. He highlights MAGS as the first ETF providing precise exposure to the Magnificent 7 via cash equities and total return swaps. Mazza also details the DRAM ETF, which offers direct access to memory semiconductor leaders like Micron and Samsung, addressing the limitations of traditional semiconductor or South Korean equity proxies. He distinguishes between structural themes like AI-driven memory demand and short-term catalysts, noting that competitor launches validate these theses. Finally, Mazza asserts that retail investors now account for 20-25% of US daily volume, up from pre-COVID levels, and influence product development through online communities.

ETFsSemiconductorsMemory Chips
15 min0 assets10 claims to verify
All insights